Administrative Department, Tangdu Hospital, Fourth Military Medical University, Xi'an City, 710038, People's Republic of China.
Pathol Oncol Res. 2012 Oct;18(4):833-9. doi: 10.1007/s12253-012-9511-2. Epub 2012 Mar 9.
FAT10, as a small ubiquitin-like modifier, plays an important role in various cellular processes, including mitosis, immune response, and apoptosis, the dys-regulation of which may arise tumorigenesis. Therefore, the aim of this study was to examine the expression of FAT10 at gene and protein levels in glioma samples with different WHO grades and its association with survival. One hundred and twenty-eight glioma specimens and 10 non-neoplastic brain tissues were collected. Immunohistochemistry assay, quantitative real-time PCR and Western blot analysis were carried out to investigate the expression of FAT10. Kaplan-Meier method and Cox's proportional hazards model were used in survival analysis. Immunohistochemistry showed that FAT10 protein was over-expressed in glioma tissues. FAT10 mRNA and protein levels were both higher in glioma compared to control on real-time PCR and Western blot analysis (both P < 0.001). Additionally, its expression levels increase from grade I to grade IV glioma according to the results of real-time PCR, immunohistochemistry analysis and Western blot. Moreover, the survival rate of FAT10-positive patients was significantly lower than that of FAT10-negative patients (P < 0.001). We further confirmed that the increased expression of FAT10 was a significant and independent prognostic indicator in glioma by multivariate analysis (P < 0.001). Our data provides convincing evidence for the first time that the increased expression of FAT10 at gene and protein levels is correlated with poor outcome in patients with glioma. FAT10 may promote the aggressiveness of glioma and may be a potential prognosis predictor of glioma.
FAT10 作为一种小型泛素样修饰物，在多种细胞过程中发挥重要作用，包括有丝分裂、免疫反应和细胞凋亡，其失调可能导致肿瘤发生。因此，本研究旨在检查不同 WHO 分级的胶质瘤样本中 FAT10 在基因和蛋白水平的表达及其与生存的关系。收集了 128 例胶质瘤标本和 10 例非肿瘤性脑组织。通过免疫组织化学检测、实时定量 PCR 和 Western blot 分析来研究 FAT10 的表达。采用 Kaplan-Meier 方法和 Cox 比例风险模型进行生存分析。免疫组织化学显示 FAT10 蛋白在胶质瘤组织中过表达。实时 PCR 和 Western blot 分析显示，与对照组相比，FAT10 mRNA 和蛋白水平在胶质瘤中均升高（均 P<0.001）。此外，根据实时 PCR、免疫组化分析和 Western blot 的结果，FAT10 的表达水平从 I 级胶质瘤增加到 IV 级胶质瘤。此外，FAT10 阳性患者的生存率明显低于 FAT10 阴性患者（P<0.001）。通过多变量分析进一步证实，FAT10 表达增加是胶质瘤的一个显著且独立的预后指标（P<0.001）。我们的数据首次提供了令人信服的证据，表明 FAT10 在基因和蛋白水平的表达增加与胶质瘤患者的不良预后相关。FAT10 可能促进胶质瘤的侵袭性，可能成为胶质瘤潜在的预后预测因子。
